 Nitriles
"Nitriles" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Organic compounds containing the -CN radical. The concept is distinguished from CYANIDES, which denotes inorganic salts of HYDROGEN CYANIDE.
| Descriptor ID |
D009570
|
| MeSH Number(s) |
D02.626
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Nitriles".
Below are MeSH descriptors whose meaning is more specific than "Nitriles".
This graph shows the total number of publications written about "Nitriles" by people in this website by year, and whether "Nitriles" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 2 | 2 | | 1999 | 0 | 1 | 1 | | 2000 | 0 | 1 | 1 | | 2001 | 0 | 3 | 3 | | 2002 | 0 | 2 | 2 | | 2003 | 0 | 3 | 3 | | 2004 | 0 | 1 | 1 | | 2007 | 1 | 2 | 3 | | 2008 | 1 | 3 | 4 | | 2009 | 1 | 4 | 5 | | 2010 | 0 | 3 | 3 | | 2011 | 1 | 4 | 5 | | 2012 | 0 | 6 | 6 | | 2013 | 3 | 5 | 8 | | 2014 | 3 | 3 | 6 | | 2015 | 2 | 8 | 10 | | 2016 | 1 | 3 | 4 | | 2017 | 0 | 7 | 7 | | 2018 | 3 | 3 | 6 | | 2019 | 3 | 1 | 4 | | 2020 | 2 | 2 | 4 | | 2021 | 2 | 6 | 8 | | 2022 | 1 | 2 | 3 | | 2023 | 0 | 1 | 1 | | 2024 | 0 | 5 | 5 |
To return to the timeline, click here.
Below are the most recent publications written about "Nitriles" by people in Profiles.
-
Balestra T, Niswander LM, Bagashev A, Loftus JP, Ross SL, Chen RK, McClellan SM, Junco JJ, B?rcenas L?pez DA, Rabin KR, Fry TJ, Tasian SK. Co-targeting of the thymic stromal lymphopoietin receptor to decrease immunotherapeutic resistance in CRLF2-rearranged Ph-like and Down syndrome acute lymphoblastic leukemia. Leukemia. 2025 Mar; 39(3):555-567.
-
Carrel A, Napoli E, Hixson K, Carlsen J, Cruz Del Angel Y, Strode D, Busquet N, Kumar V, Wempe MF, Russek SJ, Brooks-Kayal AR. Ruxolitinib-dependent reduction of seizure load and duration is accompanied by spatial memory improvement in the rat pilocarpine model of temporal lobe epilepsy. Neurotherapeutics. 2025 Mar; 22(2):e00506.
-
Simpson EL, Augustin M, Tha?i D, Misery L, Armstrong AW, Blauvelt A, Papp KA, Szepietowski JC, Boguniewicz M, Kwatra SG, Kallender H, Sturm D, Ren H, Kircik L. Ruxolitinib Cream Monotherapy Improved Symptoms and Quality of Life in Adults and Adolescents with Mild-to-Moderate Atopic Dermatitis: Patient-Reported Outcomes from Two Phase III Studies. Am J Clin Dermatol. 2025 Jan; 26(1):121-137.
-
Kawut SM, Feng R, Ellenberg SS, Zamanian R, Bull T, Chakinala M, Mathai SC, Hemnes A, Lin G, Doyle M, Andrew R, MacLean M, Stasinopoulos I, Austin E, DeMichele A, Shou H, Minhas J, Song N, Moutchia J, Ventetuolo CE. Pulmonary Hypertension and Anastrozole (PHANTOM): A Randomized, Double-Blind, Placebo-Controlled Trial. Am J Respir Crit Care Med. 2024 Nov 01; 210(9):1143-1151.
-
Eule CJ, Kuna EM, Robin TP, Gershman B, Flaig TW, Kim SP. Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer: An Analysis of Real-World Practice Patterns from the CancerLinQ Database. Urol Oncol. 2024 Dec; 42(12):447.e17-447.e24.
-
Chen TT, David AP, Gordon SE, McLaughlin L. Ruxolitinib dosing for acute graft-versus-host disease in a pediatric patient receiving continuous renal replacement therapy. Pediatr Blood Cancer. 2024 Jan; 71(1):e30754.
-
Koseoglu E, Sungur N, Muhtaroglu S, Zararsiz G, Eken A. The Beneficial Clinical Effects of Teriflunomide in Experimental Autoimmune Myasthenia Gravis and the Investigation of the Possible Immunological Mechanisms. Cell Mol Neurobiol. 2023 Jul; 43(5):2071-2087.
-
Steinman L, Fox E, Hartung HP, Alvarez E, Qian P, Wray S, Robertson D, Huang D, Selmaj K, Wynn D, Cutter G, Mok K, Hsu Y, Xu Y, Weiss MS, Bosco JA, Power SA, Lee L, Miskin HP, Cree BAC. Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis. N Engl J Med. 2022 08 25; 387(8):704-714.
-
Ho AL, Foster NR, Zoroufy AJ, Campbell JD, Worden F, Price K, Adkins D, Bowles DW, Kang H, Burtness B, Sherman E, Morton R, Morris LGT, Nadeem Z, Katabi N, Munster P, Schwartz GK. Phase II Study of Enzalutamide for Patients With Androgen Receptor-Positive Salivary Gland Cancers (Alliance A091404). J Clin Oncol. 2022 12 20; 40(36):4240-4249.
-
Lunding LP, Skouras DB, Vock C, Dinarello CA, Wegmann M. The NLRP3 inflammasome inhibitor, OLT1177? , ameliorates experimental allergic asthma in mice. Allergy. 2022 03; 77(3):1035-1038.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|